NASDAQ:GALT

Galectin Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy GALT

*Your capital is at risk

$2.80

-0.0250 (-0.88%)

At Close: Jun 22, 2026

Galectin Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -62.92. In total, the insiders bought 2.32M and sold 817.27K GALT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-62.92
● Buy	2.32M shares
● Sell	817.27K shares
67% Buy Activity Weak Negative Correlation
Sell Signal Medium Confidence Dec 03, 2025 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -62.92. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 26, 2026 Buy	Stock option (right to buy) M-Exempt	Jamil Khurram Chief Medical Officer	Officer	568 Value: $699
May 26, 2026 Sell	Common Stock S-Sale	Jamil Khurram Chief Medical Officer	Officer	568 Value: $2K
May 26, 2026 Buy	Common Stock M-Exempt	Jamil Khurram Chief Medical Officer	Officer	568 Value: $699
Mar 12, 2026 Buy	Stock option (right to buy) A-Award	Brem Henry Director	Director	60 000 Value: $189.6K
Mar 12, 2026 Buy	Common Stock	Brem Henry Director	Director	0 Value: $0
Feb 06, 2026 Buy	Common Stock P-Purchase	Eldred Kary Director	Director	300 Value: $810
Jan 16, 2026 Buy	Stock option (right to buy) A-Award	Lewis Joel President And CEO	CEO / President	91 000 Value: $276.6K
Jan 16, 2026 Buy	Stock option (right to buy) A-Award	Shlevin Harold H. Director	Director	60 000 Value: $182.4K
Jan 16, 2026 Buy	Stock option (right to buy) A-Award	Omenn Gilbert S Director	Director	60 000 Value: $182.4K
Jan 16, 2026 Buy	Stock option (right to buy) A-Award	Amelio Gilbert F Director	Director	60 000 Value: $182.4K
Jan 16, 2026 Buy	Stock option (right to buy) A-Award	Schwartz Elissa J. Director	Director	60 000 Value: $182.4K
Jan 16, 2026 Buy	Common Stock A-Award	Uihlein Richard E	Director	13 158 Value: $40.0K
Jan 16, 2026 Buy	Stock option (right to buy) A-Award	Uihlein Richard E	Director	60 000 Value: $182.4K
Jan 16, 2026 Buy	Stock option (right to buy) A-Award	Zordani Richard A. Jr. Director	Director	60 000 Value: $182.4K
Jan 16, 2026 Buy	Stock option (right to buy) A-Award	Jamil Khurram Chief Medical Officer	Officer	65 000 Value: $197.6K
Jan 16, 2026 Buy	Stock option (right to buy) A-Award	Callicutt Jack W Chief Financial Officer	C-Suite Officer	65 000 Value: $197.6K
Jan 16, 2026 Buy	Restricted Stock Unit A-Award	Callicutt Jack W Chief Financial Officer	C-Suite Officer	100 000 Value: $304.0K
Jan 16, 2026 Buy	Stock option (right to buy) A-Award	Lewis Joel President And CEO	CEO / President	84 000 Value: $255.4K
Jan 16, 2026 Buy	Restricted Stock Unit A-Award	Lewis Joel President And CEO	CEO / President	120 000 Value: $364.8K
Jan 16, 2026 Buy	Stock option (right to buy) A-Award	Eldred Kary Director	Director	60 000 Value: $182.4K
Jan 16, 2026 Buy	Stock option (right to buy) A-Award	Freeman Kevin D Director	Director	60 000 Value: $182.4K
Jan 16, 2026 Buy	Restricted Stock Unit A-Award	Jamil Khurram Chief Medical Officer	Officer	100 000 Value: $304.0K
Jan 16, 2026 Buy	Stock option (right to buy) A-Award	Carson Benjamin Sr Director	Director	60 000 Value: $182.4K
Jan 06, 2026 Sell	Common Stock S-Sale	Jamil Khurram Chief Medical Officer	Officer	21 446 Value: $78.2K
Jan 06, 2026 Sell	Common Stock S-Sale	Callicutt Jack W Chief Financial Officer	C-Suite Officer	20 354 Value: $74.7K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT GALECTIN THERAPEUTICS INC.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatiti...

Read Full Profile Here